Supporting NAD+ levels
The most consistent finding with NR is that taking it can raise NAD-related markers in the body.
Explore the research →NAD+ PRECURSOR & HUMAN RESEARCH
NR
One of the most studied NAD+ precursors, NR is the focus of human research into cellular energy, metabolism and healthy ageing.
NAD+ levelsMetabolic healthMitochondrial biology
Substantial human biomarker evidenceNR reliably engages NAD metabolism in many human studies, while downstream clinical benefits are less consistent and often endpoint-specific.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in NR?
NR gives the body another way to make NAD+, which is why it attracts interest around energy, metabolism and healthy ageing. Because NAD+ is involved in everyday cellular energy and maintenance, people are interested in whether supporting its levels could help preserve energy and healthy function over time.
Metabolic health
Researchers have looked at whether those NAD+ changes translate into improvements in blood pressure, insulin sensitivity and other metabolic measures.
Explore the research →Muscle, energy & mitochondria
NR is also explored for maintaining muscle function, energy and the health of the mitochondria that help power our cells.
Explore the research →Healthy ageing
Like NMN, much of the wider interest in NR comes from the idea of supporting NAD+ as levels and metabolism change with age.
Explore the research →THE SCIENCE BIT
A vitamin-like route into NAD+ production.
Nicotinamide riboside, or NR, is a precursor used in NAD+ metabolism. NR kinases convert it to NMN, which can then be converted into NAD+.
That gives researchers a way to influence NAD-related biomarkers. It does not mean that every extra molecule becomes more energy or a longer life; those outcomes need separate trials.
See the studies & trials →- NR
- A NAD precursor
- NR kinases
- Convert NR to NMN
- NAD+
- Energy and cell-regulation chemistry
How this connects to the research
Human studies show changes in NAD-related measures; clinical effects vary by setting.
FROM MOLECULE TO TISSUE
Where NR connects with the body
These are the tissues and biological systems behind the interest in NR.
- Cells
- The NAD salvage pathway.
- Muscle
- Energy and function studies.
- Other tissues
- Metabolic and ageing research.
The research behind the interest
Supporting NAD+ levels
The most consistent finding with NR is that taking it can raise NAD-related markers in the body.
Multiple human trials have demonstrated increases in NAD-related biomarkers after oral NR.
Strong human biomarker evidenceExplore the studies →Metabolic health
Researchers have looked at whether those NAD+ changes translate into improvements in blood pressure, insulin sensitivity and other metabolic measures.
Results are mixed: some studies show encouraging signals while others find little or no meaningful change, depending on the population and outcome measured.
Mixed human evidenceExplore the studies →Muscle, energy & mitochondria
NR is also explored for maintaining muscle function, energy and the health of the mitochondria that help power our cells.
Changes in NAD-related biology are clearer than consistent improvements in strength, endurance or everyday physical function.
Developing evidenceExplore the studies →Healthy ageing
Like NMN, much of the wider interest in NR comes from the idea of supporting NAD+ as levels and metabolism change with age.
Human research has not yet shown that NR produces a broad anti-ageing effect or extends lifespan.
Biological rationale · outcomes uncertainExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableChronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults ↗
24 healthy middle-aged and older adults
OralTwice dailyTwo 6-week treatment periods
NR was well tolerated and increased blood cellular NAD+-related metabolites.
Exploratory cardiovascular findings generated hypotheses around blood pressure and arterial stiffness rather than establishing clinical benefit.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceStrong
4/5 evidence depth
✓
Clinical efficacyLimited
2/5 evidence depth
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
◇
Safety evidenceStrong
4/5 evidence depth
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
HOW TO READ THESE SCORESDeveloping preclinical evidence · strong human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
NR research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01NAD+ levels
RESEARCH AREA 02Metabolic health
RESEARCH AREA 03Mitochondrial biology
RESEARCH AREA 04Healthy ageing
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with NR
NR is explored as a practical way to raise NAD-related metabolites, particularly for energy, metabolic health and ageing. It has a useful human evidence base, but stronger biomarker results than day-to-day outcome results.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Less depletion during ordinary activity
People hope that increasing NAD availability will translate into steadier everyday energy. This is a practical quality-of-life goal, separate from confirming that a blood biomarker rose.
- What makes a report informative
- Fatigue and function during familiar daily activities.
- What can muddy the picture
- A measurable NAD increase does not guarantee a noticeable energy benefit.
Exercise and recovery capacity
Interest includes endurance, tolerating training and feeling recovered afterwards. The useful question is whether performance changes under similar conditions, not whether the cellular mechanism sounds plausible.
- What makes a report informative
- Comparable activity duration, effort and recovery.
- What can muddy the picture
- Training adaptation, sleep and diet can produce the same changes.
Healthy ageing and cellular maintenance
People interested in prevention want to remain active and mentally capable as they get older. The attraction comes from NAD-dependent biology, but individual supplement experiences cannot answer a lifespan question.
- What makes a report informative
- Specific changes in capability and tolerability.
- What can muddy the picture
- Long-term healthy-ageing benefit needs outcomes beyond NAD measurements.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Raises NAD+
Human findings & limits
Randomized human studies consistently show increases in blood NAD-related metabolites after oral NR.
Laboratory & animal context
NR feeds into the NAD salvage pathway and has strong mechanistic support.
What this means: Target engagement is well supported; clinical benefit still needs to be judged separately.
More energy and better exercise
Human findings & limits
Changes in NAD biology have not consistently produced meaningful improvements in strength, endurance or everyday energy.
Laboratory & animal context
Mitochondrial biology provides a rationale but does not guarantee a perceptible effect.
What this means: A plausible goal with inconsistent human outcome evidence.
Healthy-ageing support
Human findings & limits
Trials explore vascular, metabolic and muscle outcomes, but do not demonstrate slower ageing or longer life.
Laboratory & animal context
Age-related changes in NAD biology drive the hypothesis.
What this means: An active field rather than an established anti-ageing treatment.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
NR has multiple human supplementation studies, but trial doses and outcomes differ by population and should not be converted into a universal clinical regimen.
PUBLISHED HUMAN RESEARCH
View source ↗Healthy middle-aged and older adult crossover trial ↗
Healthy adults aged 55–79
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Healthy adults aged 55–79. Route: Taken by mouth. The study lasted 6 weeks per treatment period. The figures below describe the research design, not a personal schedule.
| First amount studied | 500 mg twice daily |
|---|---|
| How often? | Twice daily |
| How was it given? | Taken by mouth |
| How long? | 6 weeks per treatment period |
See the exact study wording +
Start / initial: 500 mg twice daily
End / target: 500 mg twice daily
Frequency: Twice daily
Route: Oral
Study duration: 6 weeks per treatment period
Research protocol used to examine tolerability and NAD+ metabolism; not a general dosing recommendation.
COMMUNITY DISCUSSION
Supplement discussion · human trial exposure availableWhat people commonly discuss
STARTING APPROACHES
250–300 mg once daily is a common lower starting range in supplement discussions.
DURATION / CYCLES
500–1,000 mg per day has appeared in human research and community use, often reviewed after six-to-twelve weeks.
MAINTENANCE DISCUSSION
Longer-term daily use is common, but no universal evidence-based maintenance dose or cycling schedule has been established.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Twice-daily oral human-study example
Human trial · specific study populationHealthy middle-aged and older adults received 500 mg twice daily, with morning and evening meals, for six weeks. Each calendar entry is 500 mg; two entries make 1,000 mg per day. This does not establish a longevity benefit.
Form and route: Oral nicotinamide riboside
| Calendar stage | Amount each time |
|---|---|
| Weeks 1–6 | 500 mg |
Frequency: Every day · 2 entries per scheduled day.
The added evening time is an editable placeholder. The copy stops after six weeks.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
Human trials support short-term tolerability, not every long-term claim
What the current evidence saysNR has more direct human exposure than many research compounds on the site. Even so, studies are usually modest in size and duration, and cannot settle multi-year safety, every medicine interaction or the quality of all retail products.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Why this matters
NR, NMN, NADH and direct NAD+ are related but distinct. Doses and outcomes should not be transferred between them as though they were interchangeable.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
3 sourcesSources used on this profile
Peer-reviewed human trialChronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adultsNature Communications ↗Original publicationChronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adultsJournal / DOI ↗Bibliographic recordChronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adultsPubMed ↗
CURRENT STATUS
How to interpret its position today
Human supplementation research
Oral NR reliably changes NAD-related biomarkers. A broad anti-ageing or disease-treatment claim has not been established.
Nature Communications trial ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.